Became law November 12, 2025 (Pub. L. 119-37)
H.R. 5371 · Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 · Enrolled The final text both chambers passed, sent to the President to sign. If signed, it becomes law.
Became law as Public Law 119-37
This is now the law; the Code below already includes it. We hold no earlier text of the Code to compare it with, so its changes are not marked line by line: each section's versions show its text before and after.
2 U.S.C. § 2062 House of Representatives Child Care Center
3 changes the bill asks for here, 2 carried out
- Carried out:
by redesignating subparagraph (C) as subparagraph (D); and
The section already has a provision under this letter or number, so it would have two.
- Carried out:
by inserting after subparagraph (B) the following new subparagraph:
(C) The payment of telecommunications expenses for the Center, to include voicemail boxes, land lines, and cell phones for Center employees, in connection with the provision of child care services and as needed for critical and emergent communications..
- Not carried out:
Section 312(d)(3)(A) of such Act (2 U.S.C. 2062(d)(3)(A)) is amended by inserting
and assistant directors
afterdirector
.The law already reads this way: § 2062(d)(3)(A) already has “and assistant directors”.
Technical detail
already reads “and assistant directors” at that place in /us/usc/t2/s2062/d/3/A
This law puts a provision under a letter or number this section already has. The Code shown already includes the law, so the provision there may be the one it added.
1 of the 3 changes this law makes here is already in the Code shown, which includes the law, so it is not marked.
§ 2062(d)Salaries and expenses; funding limits(3)–(4)
Start of § 2062 to (d)(3) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (3)(A) | (A) | (A) | ||
| The payment of the salary of the director and assistant directors of the center, and, at the option of the Chief Administrative Officer during an emergency situation, the payment of the salary of other employees of the Center. | The payment of the salary of the director and assistant directors of the center, and, at the option of the Chief Administrative Officer during an emergency situation, the payment of the salary of other employees of the Center. | |||
| (3)(B) | (B) | (B) | ||
| The cost of training classes and conferences for individuals employed by the center in connection with the provision of child care services, together with the cost of travel (including transportation and subsistence) incurred in connection with such classes and conferences. | The cost of training classes and conferences for individuals employed by the center in connection with the provision of child care services, together with the cost of travel (including transportation and subsistence) incurred in connection with such classes and conferences. | |||
| (3)(C) | (C) [inserted: ] | |||
| [inserted: The payment of telecommunications expenses for the Center, to include voicemail boxes, land lines, and cell phones for Center employees, in connection with the provision of child care services and as needed for critical and emergent communications.] | ||||
| (3)(D) | [inserted: (D)] | |||
| The payment of telecommunications expenses for the Center, to include voicemail boxes, land lines, and cell phones for Center employees, in connection with the provision of child care services and as needed for critical and emergent communications. | The payment of telecommunications expenses for the Center, to include voicemail boxes, land lines, and cell phones for Center employees, in connection with the provision of child care services and as needed for critical and emergent communications. | |||
| (3)(D) | (D) | (D) | ||
| During an emergency situation, the payment of such other expenses for activities carried out under this section as the Chief Administrative Officer determines appropriate. | During an emergency situation, the payment of such other expenses for activities carried out under this section as the Chief Administrative Officer determines appropriate. | |||
| (4) | (4) | (4) | ||
| In the case of a child of an employee of the center who is furnished care at the center, the Chief Administrative Officer shall reduce the amount of tuition otherwise charged with respect to such child during a month by the greater of— | In the case of a child of an employee of the center who is furnished care at the center, the Chief Administrative Officer shall reduce the amount of tuition otherwise charged with respect to such child during a month by the greater of— | |||
Rest of § 2062 unchanged
2 U.S.C. § 6628 Treatment of electronic services provided by Sergeant at Arms
11 changes the bill asks for here, 11 carried out
- Carried out:
by redesignating paragraphs (3) through (7) as paragraphs (5) through (9), respectively;
- Carried out:
by redesignating paragraph (2) as paragraph (3);
- Carried out:
by inserting after paragraph (1) the following:
(2) the term “covered data” means any electronic mail or other electronic or data communication, other data (including metadata), or other information;;
- Carried out:
by inserting after paragraph (3), as so redesignated, the following:
(4) the term “legal process” does not include a subpoena issued in accordance with the Rules of Procedure of the Select Committee on Ethics of the Senate;;
- Carried out:
by striking paragraph (8), as so redesignated, and inserting the following:
(8) the term “Senate data”, with respect to a Senate office—(A) means covered data of the Senate office; and (B) with respect to an individual described in paragraph (9) acting in a personal capacity, only means covered data that is transmitted, processed, or stored through the …
- Carried out:
by inserting
(without regard to whether the Senator is acting in his or her official capacity, including acting in a personal capacity and acting through his or her campaign for elected office)
aftera Senator
; - Carried out:
by inserting
(whether acting in his or her personal or official capacity)
afteran officer of the Senate
; and - Carried out:
by striking the period at the end and inserting
(whether acting in his or her personal or official capacity); and
; and - Carried out:
by adding at the end the following:
(10) the term “target of a criminal investigation” means a person—(A) as to whom the prosecutor or the grand jury has substantial evidence linking that person to the commission of a crime; (B) who, in the judgment of the prosecutor, is a putative defendant; and (C) whom the …
- Carried out:
by redesignating subsections (d) through (h) as subsections (e) through (i), respectively; and
- Carried out:
by striking subsection (c) and inserting the following:
(c) Notification.—(1) By providers.—(A) In general.—If any provider for a Senate office receives any legal process seeking disclosure of Senate data of the Senate office that is transmitted, processed, or stored (whether temporarily or otherwise) through the use of an electronic …
§ 6628(a)–(i)
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| § 6628. Treatment of electronic services provided by Sergeant at Arms | § 6628. Treatment of electronic services provided by Sergeant at Arms | |||
| (a) | (a) In general | (a) In general | ||
| In this section— | In this section— | |||
| (a)(1) | (1) | (1) | ||
| the term “agent of the Office of the SAA” includes a provider of electronic communication service or remote computing service commissioned or used through the Office of the SAA by a Senate office to provide such services to the Senate office; | the term “agent of the Office of the SAA” includes a provider of electronic communication service or remote computing service commissioned or used through the Office of the SAA by a Senate office to provide such services to the Senate office; | |||
| (a)(2) | (2) [inserted: ] | |||
| [inserted: the term “covered data” means any electronic mail or other electronic or data communication, other data (including metadata), or other information;] | ||||
| (a)(3) | [inserted: (3)] | |||
| the term “electronic communication service” has the meaning given that term in section 2510 of title 18; | the term “electronic communication service” has the meaning given that term in section 2510 of title 18; | |||
| (a)(4) | (4) [inserted: ] | |||
| [inserted: the term “legal process” does not include a subpoena issued in accordance with the Rules of Procedure of the Select Committee on Ethics of the Senate;] | ||||
| (a)(5) | [inserted: (5)] | |||
| the term “Office of the SAA” means the Office of the Sergeant at Arms and Doorkeeper of the Senate; | the term “Office of the SAA” means the Office of the Sergeant at Arms and Doorkeeper of the Senate; | |||
| (a)(6) | [inserted: (6)] | |||
| the term “provider for a Senate office” means a provider of electronic communication service or remote computing service directly commissioned or used by a Senate office to provide such services; | the term “provider for a Senate office” means a provider of electronic communication service or remote computing service directly commissioned or used by a Senate office to provide such services; | |||
| (a)(7) | [inserted: (7)] | |||
| the term “remote computing service” has the meaning given that term in section 2711 of title 18; | the term “remote computing service” has the meaning given that term in section 2711 of title 18; | |||
| (a)(8) | [inserted: (8)] | |||
| [inserted: the term “Senate data”, with respect to a Senate office—] | ||||
| (a)(8)(A) | (A) [inserted: ] | |||
| [inserted: means covered data of the Senate office; and] | ||||
| (a)(8)(B) | (B) [inserted: ] | |||
| [inserted: with respect to an individual described in paragraph (9) acting in a personal capacity, only means covered data that is transmitted, processed, or stored through the use of an electronic system established, maintained, or operated, or the use of electronic services provided, by—] | ||||
| (a)(8)(B)(i) | (i) [inserted: ] | |||
| [inserted: a provider for the Senate office, if the Senate office or the Office of the SAA has notified the provider for a Senate office that the applicable device or account is a device or account of the Senate office; or] | ||||
| (a)(8)(B)(ii) | (ii) [inserted: ] | |||
| [inserted: the Office of the SAA or an officer, employee, or agent of the Office of the SAA, if the Senate office has notified the Office of the SAA that the applicable device or account is a device or account of the Senate office;] | ||||
| (a)(6) | ||||
| (a)(9) | [inserted: (9)] | |||
| the term “Senate office” means a committee or office of the Senate, including a Senator, an officer of the Senate, or an employee of, intern at, or other agent of a committee or office of the Senate | the term “Senate office” means a committee or office of the Senate, including a Senator[inserted: (without regard to whether the Senator is acting in his or her official capacity], [inserted: including acting in a personal capacity and acting through his or her campaign for elected office), ]an officer of the Senate[inserted: (whether acting in his or her personal or official capacity)], or an employee of, intern at, or other agent of a committee or office of the Senate[inserted: (whether acting in his or her personal or official capacity); and] | |||
| (a)(10) | (10) [inserted: ] | |||
| [inserted: the term “target of a criminal investigation” means a person—] | ||||
| (a)(10)(A) | (A) [inserted: ] | |||
| [inserted: as to whom the prosecutor or the grand jury has substantial evidence linking that person to the commission of a crime;] | ||||
| (a)(10)(B) | (B) [inserted: ] | |||
| [inserted: who, in the judgment of the prosecutor, is a putative defendant; and] | ||||
| (a)(10)(C) | (C) [inserted: ] | |||
| [inserted: whom the prosecutor, before the date of the acquisition, subpoena, search, accessing, or disclosure of the Senate data at issue, has formally designated as a target in official records, which shall not include any such designation that was made after such date that purports to be retroactive.] | ||||
| (b) | (b) Treatment | (b) Treatment | ||
| (b)(1) | (1) Retaining possession | (1) Retaining possession | ||
| (b)(1)(A) | (A) In general | (A) In general | ||
| A Senate office shall be deemed to retain possession of any Senate data of the Senate office, without regard to the use by the Senate office of any individual or entity described in paragraph (2) for the purposes of any function or service described in paragraph (2). | A Senate office shall be deemed to retain possession of any Senate data of the Senate office, without regard to the use by the Senate office of any individual or entity described in paragraph (2) for the purposes of any function or service described in paragraph (2). | |||
| (b)(1)(B) | (B) Rule of construction | (B) Rule of construction | ||
| Subparagraph (A) shall not be construed to limit the use by an intended recipient of any Senate data from a Senate office. | Subparagraph (A) shall not be construed to limit the use by an intended recipient of any Senate data from a Senate office. | |||
| (b)(2) | (2) Sergeant at Arms and providers for a Senate office | (2) Sergeant at Arms and providers for a Senate office | ||
| The Office of the SAA, any officer, employee, or agent of the Office of the SAA, and any provider for a Senate office shall not be treated as acquiring possession, custody, or control of any Senate data by reason of its being transmitted, processed, or stored (whether temporarily or otherwise) through the use of an electronic system established, maintained, or operated, or the use of electronic services provided, in whole or in part by the Office of the SAA, the officer, employee, or agent of the Office of the SAA, or the provider for the Senate office. | The Office of the SAA, any officer, employee, or agent of the Office of the SAA, and any provider for a Senate office shall not be treated as acquiring possession, custody, or control of any Senate data by reason of its being transmitted, processed, or stored (whether temporarily or otherwise) through the use of an electronic system established, maintained, or operated, or the use of electronic services provided, in whole or in part by the Office of the SAA, the officer, employee, or agent of the Office of the SAA, or the provider for the Senate office. | |||
| (c) | (c) Notification | (c) Notification[inserted: .—] | ||
| (c)(1) | (1) [inserted: By providers.—] | |||
| (c)(1)(A) | (A) [inserted: In general.—] | |||
| [inserted: If any provider for a Senate office receives any legal process seeking disclosure of Senate data of the Senate office that is transmitted, processed, or stored (whether temporarily or otherwise) through the use of an electronic system established, maintained, or operated, or the use of electronic services provided, in whole or in part, by the provider for a Senate office, the provider for a Senate office shall notify the Senate office and, unless specified otherwise by the Senate office, the Office of the SAA in writing.] | ||||
| (c)(1)(B) | (B) [inserted: No limitations on notice.—] | |||
| [inserted: A provider for a Senate office shall not be barred from providing notice to a Senate office and the Office of the SAA under subparagraph (A) by operation of any court order, any statutory provision, any other provision of law, any rule of civil or criminal procedure, or any other rule, regulation, or policy.] | ||||
| (c)(1)(C) | (C) [inserted: Limitation on liability.—] | |||
| [inserted: A provider for a Senate office shall not be liable under any criminal or civil law for providing notice to a Senate office or the Office of the SAA under this paragraph.] | ||||
| (c)(2) | (2) [inserted: By saa.—] | |||
| (c)(2)(A) | (A) [inserted: In general.—] | |||
| [inserted: If the Office of the SAA or any officer, employee, or agent of the Office of the SAA receives any legal process seeking disclosure of Senate data of a Senate office that is transmitted, processed, or stored (whether temporarily or otherwise) through the use of an electronic system established, maintained, or operated, or the use of electronic services provided, in whole or in part, by the Office of the SAA or the officer, employee, or agent of the Office of the SAA, the Office of the SAA or the officer, employee, or agent of the Office of the SAA shall notify a Senate office in writing.] | ||||
| (c)(2)(B) | (B) [inserted: No limitations on notice.—] | |||
| [inserted: The Office of the SAA and any officer, employee, or agent of the Office of the SAA shall not be barred from providing notice to a Senate office under subparagraph (A) by operation of any court order, any statutory provision, any other provision of law, any rule of civil or criminal procedure, or any other rule, regulation, or policy.] | ||||
| (c)(2)(C) | (C) [inserted: Limitation on liability.—] | |||
| [inserted: The Office of the SAA and any officer, employee, or agent of the Office of the SAA shall not be liable under any criminal or civil law for providing notice to a Senate office under this paragraph.] | ||||
| (c)(3) | (3) [inserted: Special rule for target and non-target investigations.—] | |||
| (c)(3)(A) | (A) [inserted: Target investigations.—] | |||
| (c)(3)(A)(i) | (i) [inserted: In general.—] | |||
| [inserted: If a Senator is a target of a criminal investigation, a court may, upon application by the United States, issue an order delaying the notice required under this subsection with respect to an acquisition, subpoena, search, accessing, or disclosure of Senate data in connection with such investigation for a period of not more than 60 days if the court determines that there is reason to believe that providing notice would—] | ||||
| (c)(3)(A)(i)(I) | (I) [inserted: ] | |||
| [inserted: endanger the life or physical safety of any person;] | ||||
| (c)(3)(A)(i)(II) | (II) [inserted: ] | |||
| [inserted: result in flight from prosecution;] | ||||
| (c)(3)(A)(i)(III) | (III) [inserted: ] | |||
| [inserted: result in destruction of or tampering with evidence;] | ||||
| (c)(3)(A)(i)(IV) | (IV) [inserted: ] | |||
| [inserted: result in intimidation of potential witnesses; or] | ||||
| (c)(3)(A)(i)(V) | (V) [inserted: ] | |||
| [inserted: otherwise seriously jeopardize an investigation or unduly delay a trial.] | ||||
| (c)(3)(A)(ii) | (ii) [inserted: Renewal.—] | |||
| [inserted: The court may renew such an order for additional periods of not more than 60 days each, if the court makes a renewed determination under clause (i).] | ||||
| (c)(3)(B) | (B) [inserted: All other investigations.—] | |||
| [inserted: For any investigation in which a Senator is not a target of a criminal investigation, the notice requirements under this subsection shall apply without delay.] | ||||
| (d) | (d) [inserted: Private Cause of Action.—] | |||
| (d)(1) | (1) [inserted: Definitions.—] | |||
| [inserted: In this subsection:] | ||||
| (d)(1)(A) | (A) [inserted: Instance.—] | |||
| [inserted: The term “instance”, with respect to a violation of this section, means each discrete act constituting a violation of this section, including each individual—] | ||||
| (d)(1)(A)(i) | (i) [inserted: ] | |||
| [inserted: device, account, record, or communication channel subject to collection in a manner in violation of this section;] | ||||
| (d)(1)(A)(ii) | (ii) [inserted: ] | |||
| [inserted: nondisclosure order or judicial sealing order sought, maintained, or obtained; or] | ||||
| (d)(1)(A)(iii) | (iii) [inserted: ] | |||
| [inserted: search conducted.] | ||||
| (d)(1)(B) | (B) [inserted: Violation of this section.—] | |||
| [inserted: The term “violation of this section” means—] | ||||
| (d)(1)(B)(i) | (i) [inserted: ] | |||
| [inserted: the seeking, maintaining, or obtaining of a nondisclosure order or judicial sealing order to prevent notification of a Senator, a Senate office, or the Office of the SAA as required under subsection (c); or] | ||||
| (d)(1)(B)(ii) | (ii) [inserted: ] | |||
| [inserted: Senate data was acquired, subpoenaed, searched, accessed, or disclosed pursuant to a search, seizure, or demand for information without notice being provided as required under subsection (c).] | ||||
| (d)(2) | (2) [inserted: Cause of action.—] | |||
| [inserted: Any Senator whose Senate data, or the Senate data of whose Senate office, has been acquired, subpoenaed, searched, accessed, or disclosed in violation of this section may bring a civil action against the United States if the violation was committed by an officer, employee, or agent of the United States or of any Federal department or agency.] | ||||
| (d)(3) | (3) [inserted: Relief.—] | |||
| (d)(3)(A) | (A) [inserted: In general.—] | |||
| [inserted: If a Senator prevails on a claim under this subsection, the court shall award—] | ||||
| (d)(3)(A)(i) | (i) [inserted: ] | |||
| [inserted: for each instance of a violation of this section, the greater of statutory damages of $500,000 or the amount of actual damages;] | ||||
| (d)(3)(A)(ii) | (ii) [inserted: ] | |||
| [inserted: reasonable attorney’s fees and costs of litigation; and] | ||||
| (d)(3)(A)(iii) | (iii) [inserted: ] | |||
| [inserted: such injunctive or declaratory relief as may be appropriate.] | ||||
| (d)(3)(B) | (B) [inserted: Preliminary relief.—] | |||
| [inserted: Upon motion by a Senator, a court may award such preliminary injunctive relief as the court determines appropriate with respect to a claim under this subsection.] | ||||
| (d)(4) | (4) [inserted: Limitations and immunity.—] | |||
| (d)(4)(A) | (A) [inserted: Period of limitations.—] | |||
| [inserted: A civil action under this subsection may not be commenced later than 5 years after the applicable Senator first obtains actual notice of the violation of this section.] | ||||
| (d)(4)(B) | (B) [inserted: No immunity defense.—] | |||
| [inserted: No officer, employee, or agent of the United States or of any Federal department or agency shall be entitled to assert any form of absolute or qualified immunity as a defense to liability under this subsection.] | ||||
| (d)(5) | (5) [inserted: Waiver of sovereign immunity.—] | |||
| [inserted: The United States expressly waives sovereign immunity with respect to actions brought under this subsection.] | ||||
| (d)(6) | (6) [inserted: Affirmative defense for target investigations.—] | |||
| [inserted: It shall be an affirmative defense to an action under this subsection if the United States establishes that each of the following requirements are met:] | ||||
| (d)(6)(A) | (A) [inserted: ] | |||
| [inserted: At the time the Senate data was acquired, subpoenaed, searched, accessed, or disclosed, the Senator bringing the action was a target of a criminal investigation.] | ||||
| (d)(6)(B) | (B) [inserted: ] | |||
| [inserted: A Federal judge issued an order authorizing a delay of notice to the Senator under subsection (c)(3)(A), based on written findings meeting the requirements of such subsection.] | ||||
| (d)(6)(C) | (C) [inserted: ] | |||
| [inserted: The United States complied with the order described in subparagraph (B), including that the delay of notice did not exceed the period authorized by the court.] | ||||
| (d)(6)(D) | (D) [inserted: ] | |||
| [inserted: Any related subpoena of, warrant relating to, or access to Senate data was carried out strictly within the temporal and subject-matter scope authorized by the order, if any, authorizing the subpoena, warrant, or access.] | ||||
| (d)(7) | (7) [inserted: Construction.—] | |||
| [inserted: Nothing in this subsection shall be construed to—] | ||||
| (d)(7)(A) | (A) [inserted: ] | |||
| [inserted: limit or impair the constitutional protections afforded to Members of Congress, including to protections under article I, section 6, clause 1 of the Constitution of the United States (commonly known as the “Speech or Debate Clause”); or] | ||||
| (d)(7)(B) | (B) [inserted: ] | |||
| [inserted: restrict the authority of the Senate or any Senate office to intervene in or defend against any legal process seeking disclosure of Senate data.] | ||||
| (c) | ||||
| (e) | [inserted: (e)] Motions to quash or modify | |||
| Upon a motion made promptly by a Senate office or provider for a Senate office, a court of competent jurisdiction shall quash or modify any legal process directed to the provider for a Senate office if compliance with the legal process would require the disclosure of Senate data of the Senate office. | Upon a motion made promptly by a Senate office or provider for a Senate office, a court of competent jurisdiction shall quash or modify any legal process directed to the provider for a Senate office if compliance with the legal process would require the disclosure of Senate data of the Senate office. | |||
| (f) | [inserted: (f)] Information regarding implications of using providers | |||
| The Office of the SAA, in consultation with the Senate Legal Counsel, shall provide information to each Senate office that commissions or uses a provider of electronic communication service or remote computing service to provide such services to the Senate office regarding the potential constitutional implications and the potential impact on privileges that may be asserted by the Senate office. | The Office of the SAA, in consultation with the Senate Legal Counsel, shall provide information to each Senate office that commissions or uses a provider of electronic communication service or remote computing service to provide such services to the Senate office regarding the potential constitutional implications and the potential impact on privileges that may be asserted by the Senate office. | |||
| (g) | [inserted: (g)] Applicable privileges | |||
| Nothing in this section shall be construed to limit or supersede any applicable privilege, immunity, or other objection that may apply to the disclosure of Senate data. | Nothing in this section shall be construed to limit or supersede any applicable privilege, immunity, or other objection that may apply to the disclosure of Senate data. | |||
| (h) | [inserted: (h)] Preemption | |||
| Except as provided in this section, any provision of law or rule of civil or criminal procedure of any State, political subdivision, or agency thereof, which is inconsistent with this section shall be deemed to be preempted and superseded. | Except as provided in this section, any provision of law or rule of civil or criminal procedure of any State, political subdivision, or agency thereof, which is inconsistent with this section shall be deemed to be preempted and superseded. | |||
| (i) | [inserted: (i)] Effective date | |||
| This section shall apply to fiscal year 2005 and each fiscal year thereafter. | This section shall apply to fiscal year 2005 and each fiscal year thereafter. | |||
12 U.S.C. § 3702 Definitions
4 changes the bill asks for here, 1 carried out
- Not carried out:
Section 363 of the Multifamily Mortgage Foreclosure Act of 1981 (12 U.S.C. 3702) is amended at paragraph (2)—
We can't read how this instruction is worded yet, so it isn't shown in the text.
Technical detail
no-pattern: at paragraph (X) — - Not carried out:
in subparagraph (D), by striking
and
;“and” isn't in § 3702(2)(D) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“and” not found in /us/usc/t12/s3702/2/D - Not carried out:
in subparagraph (E), by striking the period at the end and inserting
; and
; andThe bill strikes “.” at the end of § 3702(2)(E), but the text there doesn't end with it. The law may have changed since the bill was drafted.
Technical detail
“.” is not at the end of /us/usc/t12/s3702/2/E - Carried out:
by inserting after subparagraph (E) the following:
(F) section 514 or 515 of the Housing Act of 1949 (42 U.S.C. 1484, 1485)..
The section already has a provision under this letter or number, so it would have two.
This law puts a provision under a letter or number this section already has. The Code shown already includes the law, so the provision there may be the one it added.
§ 3702(2)–(3)
Start of § 3702 to (2)(C) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (2)(D) | (D) | (D) | ||
| section 202 of the Housing Act of 1959 [12 U.S.C. 1701q], as amended by section 801 of the Cranston-Gonzalez National Affordable Housing Act; | section 202 of the Housing Act of 1959 [12 U.S.C. 1701q], as amended by section 801 of the Cranston-Gonzalez National Affordable Housing Act; | |||
| (2)(E) | (E) | (E) | ||
| section 811 of the Cranston-Gonzalez National Affordable Housing Act [42 U.S.C. 8013]; and | section 811 of the Cranston-Gonzalez National Affordable Housing Act [42 U.S.C. 8013]; and | |||
| (2)(F) | (F) [inserted: ] | |||
| [inserted: section 514 or 515 of the Housing Act of 1949 (42 U.S.C. 1484, 1485).] | ||||
| (2)(F) | (F) | (F) | ||
| section 5141 515, or 538 of the Housing Act of 1949 (42 U.S.C. 1484, 1485, 1490p–2). | section 5141 515, or 538 of the Housing Act of 1949 (42 U.S.C. 1484, 1485, 1490p–2). | |||
| (3) | (3) | (3) | ||
| “mortgage agreement” means the note or debt instrument and the mortgage instrument, deed of trust instrument, trust deed, or instrument or instruments creating the mortgage, including any instrument incorporated by reference therein (including any applicable regulatory agreement), and any instrument or agreement amending or modifying any of the foregoing; | “mortgage agreement” means the note or debt instrument and the mortgage instrument, deed of trust instrument, trust deed, or instrument or instruments creating the mortgage, including any instrument incorporated by reference therein (including any applicable regulatory agreement), and any instrument or agreement amending or modifying any of the foregoing; | |||
Rest of § 3702 unchanged
21 U.S.C. § 355 New drugs
1 change the bill asks for here, 1 carried out
- Carried out:
Section 505(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(b)) is amended by adding at the end the following:
(7) Rx-to-nonprescription switches.—(A) Meetings.—Any person planning to submit an application for an Rx-to-nonprescription switch may submit to the Secretary a written request for a meeting, for purposes of developing a plan for such application that addresses the potential …
The section already has a provision under this letter or number, so it would have two.
This law puts a provision under a letter or number this section already has. The Code shown already includes the law, so the provision there may be the one it added.
§ 355(b)–(c)
Start of § 355 to (b)(7)(E) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (b)(7)(E)(i) | (i) | (i) | ||
| supersede or modify the authority of the Secretary under section 355h of this title with respect to the regulation of OTC monograph drugs; or | supersede or modify the authority of the Secretary under section 355h of this title with respect to the regulation of OTC monograph drugs; or | |||
| (b)(7)(E)(ii) | (ii) | (ii) | ||
| authorize the disclosure by the Secretary of confidential commercial information or trade secrets. | authorize the disclosure by the Secretary of confidential commercial information or trade secrets. | |||
| (b)(7) | (7) [inserted: Rx-to-nonprescription switches.—] | |||
| (b)(7)(A) | (A) [inserted: Meetings.—] | |||
| [inserted: Any person planning to submit an application for an Rx-to-nonprescription switch may submit to the Secretary a written request for a meeting, for purposes of developing a plan for such application that addresses the potential risks to public health of such switch and the evidence necessary to support such application, including the design of any necessary studies, and the format and content of the planned application. The Secretary may grant such a meeting, as appropriate, consistent with established procedures for granting meetings with, and providing written responses to, applications under this section. Each such meeting shall be documented in meeting minutes.] | ||||
| (b)(7)(B) | (B) [inserted: Guidance.—] | |||
| (b)(7)(B)(i) | (i) [inserted: In general.—] | |||
| [inserted: Not later than 18 months after the date of enactment of this paragraph, the Secretary shall issue guidance to increase the clarity and predictability of the process and standards for approval of applications for nonprescription drugs under this section, including in the case of applications for an Rx-to-nonprescription switch, especially with respect to prescription drugs with well-established safety profiles for which an applicant may seek approval for nonprescription use.] | ||||
| (b)(7)(B)(ii) | (ii) [inserted: Contents.—] | |||
| [inserted: The guidance under clause (i) shall—] | ||||
| (b)(7)(B)(ii)(I) | (I) [inserted: ] | |||
| [inserted: describe how published reports in medical literature, any previous finding of safety or effectiveness for the drug under this section, the results of significant human experience with the drug, unpublished studies and other data, and other sources of information may be used to support an application for a nonprescription drug, including in the context of an application for an Rx-to-nonprescription switch;] | ||||
| (b)(7)(B)(ii)(II) | (II) [inserted: ] | |||
| [inserted: set forth procedures for sponsors to request meetings described in subparagraph (A) and document the recommendations made in such meetings;] | ||||
| (b)(7)(B)(ii)(III) | (III) [inserted: ] | |||
| [inserted: describe evidentiary expectations to support approval of an application for a nonprescription drug, including in the context of an application for an Rx-to-nonprescription switch, including how sponsors can demonstrate that consumers can appropriately self-select and use the drug and comprehend the nonprescription drug label; and] | ||||
| (b)(7)(B)(ii)(IV) | (IV) [inserted: ] | |||
| [inserted: provide recommendations for how mechanisms, in addition to the required Drug Facts Label, such as mobile applications and decisions aids, can be incorporated into the information submitted in support of an application for an Rx-to-nonprescription switch.] | ||||
| (b)(7)(C) | (C) [inserted: Plan to engage with stakeholders.—] | |||
| [inserted: Not later than 1 year after the date of enactment of this paragraph, the Secretary shall develop and make publicly available on the website of the Food and Drug Administration a plan to engage stakeholders on steps and factors for application holders and other stakeholders to consider in identifying approved prescription drugs that may be promising candidates for applications for an Rx-to-nonprescription switch.] | ||||
| (b)(7)(D) | (D) [inserted: Definition.—] | |||
| [inserted: For purposes of this paragraph, the term “Rx-to-nonprescription switch” means the approval of an application, or supplemental application, as applicable, submitted under this section by the holder of an approved application for a prescription drug seeking approval to market such drug as a nonprescription drug, including for—] | ||||
| (b)(7)(D)(i) | (i) [inserted: ] | |||
| [inserted: a full Rx-to-nonprescription switch, under which a drug previously approved for prescription use only is—] | ||||
| (b)(7)(D)(i)(I) | (I) [inserted: ] | |||
| [inserted: approved for nonprescription use under the same conditions as applied to the drug when approved for prescription use; or] | ||||
| (b)(7)(D)(i)(II) | (II) [inserted: ] | |||
| [inserted: approved for nonprescription use subject to one or more additional conditions for nonprescription use; and] | ||||
| (b)(7)(D)(ii) | (ii) [inserted: ] | |||
| [inserted: a partial Rx-to-nonprescription switch, under which the drug is approved for nonprescription use only under certain conditions described in the approved labeling, while the drug otherwise remains approved for prescription use only.] | ||||
| (b)(7)(E) | (E) [inserted: Rule of construction.—] | |||
| [inserted: Nothing in this paragraph shall be construed to—] | ||||
| (b)(7)(E)(i) | (i) [inserted: ] | |||
| [inserted: supersede or modify the authority of the Secretary under section 505G with respect to the regulation of OTC monograph drugs; or] | ||||
| (b)(7)(E)(ii) | (ii) [inserted: ] | |||
| [inserted: authorize the disclosure by the Secretary of confidential commercial information or trade secrets.] | ||||
| (c) | (c) Period for approval of application; period for, notice, and expedition of hearing; period for issuance of order | (c) Period for approval of application; period for, notice, and expedition of hearing; period for issuance of order | ||
| (c)(1) | (1) | (1) | ||
| Within one hundred and eighty days after the filing of an application under subsection (b), or such additional period as may be agreed upon by the Secretary and the applicant, the Secretary shall either— | Within one hundred and eighty days after the filing of an application under subsection (b), or such additional period as may be agreed upon by the Secretary and the applicant, the Secretary shall either— | |||
Rest of § 355 unchanged
21 U.S.C. § 355h Regulation of certain nonprescription drugs that are marketed without an approved drug application
3 changes the bill asks for here, 1 carried out
- Carried out:
Section 505G of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355h) is amended by adding at the end the following:
(r) Evidence and Testing Standards for Active Ingredients for Topical Administration.—(1) Evidence and testing standards for active ingredients for topical administration.—The Secretary shall—(A) in evaluating the generally recognized as safe and effective status of active …
The section already has a provision under this letter or number, so it would have two.
- Not carried out:
Section 505G(h) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355h(h)) is amended by striking
sponsors or requestors
and insertingsponsors, requestors, or organizations nominated by sponsors or requestors to represent their interests in a proceeding
.The law already reads this way: § 355h(h) already has “sponsors, requestors, or organizations nominated by sponsors or requestors to represent their interests in a proceeding”.
Technical detail
already reads “sponsors, requestors, or organizations nominated by sponsors or requestors to represent their interests in a proceeding” in /us/usc/t21/s355h/h - Not carried out:
Section 505G(b)(2)(A)(iv)(III) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355h(b)(2)(A)(iv)(III)) is amended by striking
requestors
and insertingsponsors or requestors
.The law already reads this way: § 355h(b)(2)(A)(iv)(III) already has “sponsors or requestors”.
Technical detail
already reads “sponsors or requestors” in /us/usc/t21/s355h/b/2/A/iv/III
This law puts a provision under a letter or number this section already has. The Code shown already includes the law, so the provision there may be the one it added.
2 of the 3 changes this law makes here are already in the Code shown, which includes the law, so they are not marked.
§ 355h(r)–(r)
Start of § 355h to (r)(2)(A) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (r)(2)(B) | (B) Guidance | (B) Guidance | ||
| Not later than 1 year after November 12, 2025, the Secretary shall issue new draft guidance on how sponsors can use nonclinical testing alternatives to animal testing, as appropriate, to meet safety and efficacy standards under this section for drugs intended for topical administration. | Not later than 1 year after November 12, 2025, the Secretary shall issue new draft guidance on how sponsors can use nonclinical testing alternatives to animal testing, as appropriate, to meet safety and efficacy standards under this section for drugs intended for topical administration. | |||
| (r)(3) | (3) Clarification | (3) Clarification | ||
| Nothing in this subsection shall be construed to alter, supersede, or limit the standards for making determinations of whether a drug is generally recognized as safe and effective under section 321(p) of this title or the standards set forth under section 355 of this title for determining the safety and effectiveness of drugs. | Nothing in this subsection shall be construed to alter, supersede, or limit the standards for making determinations of whether a drug is generally recognized as safe and effective under section 321(p) of this title or the standards set forth under section 355 of this title for determining the safety and effectiveness of drugs. | |||
| (r) | (r) [inserted: Evidence and Testing Standards for Active Ingredients for Topical Administration.—] | |||
| (r)(1) | (1) [inserted: Evidence and testing standards for active ingredients for topical administration.—] | |||
| [inserted: The Secretary shall—] | ||||
| (r)(1)(A) | (A) [inserted: ] | |||
| [inserted: in evaluating the generally recognized as safe and effective status of active ingredients used in nonprescription drugs intended for topical administration for purposes of subsection (a), utilize standards that allow for the use of real world evidence (as defined in section 505F(b)), as appropriate, as part of a comprehensive evaluation of scientific evidence to demonstrate the safety and effectiveness of such active ingredients, to supplement evidence from traditional clinical trials, provided that such standards allow the Secretary to evaluate whether the benefits of such active ingredients outweigh the risks; and] | ||||
| (r)(1)(B) | (B) [inserted: ] | |||
| [inserted: apply subsection (b)(6)(C) to the regulation of active ingredients used in drugs intended for topical administration.] | ||||
| (r)(2) | (2) [inserted: Non-animal testing methods for topical active ingredients.—] | |||
| (r)(2)(A) | (A) [inserted: In general.—] | |||
| [inserted: The Secretary shall consider the types of nonclinical tests described in paragraphs (1) through (4) of the first subsection (z) of section 505 (as inserted by section 3209(a)(2) of the Health Extenders, Improving Access to Medicare, Medicaid, and CHIP, and Strengthening Public Health Act of 2022 (division FF of Public Law 117–328)), or any other alternative to animal testing that the Secretary determines appropriate, in the consideration of drugs intended for topical administration under this section.] | ||||
| (r)(2)(B) | (B) [inserted: Guidance.—] | |||
| [inserted: Not later than 1 year after the date of enactment of this subsection, the Secretary shall issue new draft guidance on how sponsors can use nonclinical testing alternatives to animal testing, as appropriate, to meet safety and efficacy standards under this section for drugs intended for topical administration.] | ||||
| (r)(3) | (3) [inserted: Clarification.—] | |||
| [inserted: Nothing in this subsection shall be construed to alter, supersede, or limit the standards for making determinations of whether a drug is generally recognized as safe and effective under section 201(p) or the standards set forth under section 505 for determining the safety and effectiveness of drugs.] | ||||
21 U.S.C. § 379j–71 Definitions
4 changes the bill asks for here, 1 carried out
- Not carried out:
in clause (v), by striking
; or
and inserting a semicolon;“; or” isn't in § 379j–71(9)(A)(v) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“; or” not found in /us/usc/t21/s379j–71/9/A/v - Not carried out:
by striking
addition
and insertingthe addition
; andThe law already reads this way: § 379j–71(9)(A)(vi) already has “the addition”.
Technical detail
already reads “the addition” in /us/usc/t21/s379j–71/9/A/vi - Carried out:
by striking the period and inserting
; or
; and - Not carried out:
by adding at the end the following:
(vii) the addition or modification of a testing procedure applicable to one or more OTC monograph drugs, provided that such additional or modified testing procedure reflects a voluntary consensus standard with respect to pharmaceutical quality that is—(I) established by a …
The law already reads this way: § 379j–71(9)(A)(vii) is already as the bill would have it.
Technical detail
already there: /us/usc/t21/s379j–71/9/A/vii reads as the bill would have it
2 of the 4 changes this law makes here are already in the Code shown, which includes the law, so they are not marked.
§ 379j–71(9)(A)“Tier 2 OTC monograph order request” means…(v)–(vii)
Start of § 379j–71 to (9)(A)(iv) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (v) | (v) | (v) | ||
| a change to ingredient nomenclature to align with nomenclature of a standards-setting organization; | a change to ingredient nomenclature to align with nomenclature of a standards-setting organization; | |||
| (vi) | (vi) | (vi) | ||
| the addition of an interchangeable term in accordance with section 330 | the addition of an interchangeable term in accordance with section 330[inserted: ;] [inserted: or1 ]of title 21, Code of Federal Regulations (or any successor regulations); or | |||
| (vii) | (vii) | (vii) | ||
| the addition or modification of a testing procedure applicable to one or more OTC monograph drugs, provided that such additional or modified testing procedure reflects a voluntary consensus standard with respect to pharmaceutical quality that is— | the addition or modification of a testing procedure applicable to one or more OTC monograph drugs, provided that such additional or modified testing procedure reflects a voluntary consensus standard with respect to pharmaceutical quality that is— | |||
| (vii)(I) | (I) | (I) | ||
| established by a national or international standards development organization; and | established by a national or international standards development organization; and |
Rest of § 379j–71 unchanged
21 U.S.C. § 379j–72 Authority to assess and use OTC monograph fees
26 changes the bill asks for here, 8 carried out
- Not carried out:
by striking
on December 31 of the fiscal year or at any time during the preceding 12-month period
and insertingat any time during the applicable period specified in clause (ii) for a fiscal year
;“on December 31 of the fiscal year or at any time during the preceding 12-month period” isn't in § 379j–72(a)(1)(A) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“on December 31 of the fiscal year or at any time during the preceding 12-month period” not found in /us/usc/t21/s379j–72/a/1/A - Not carried out:
by striking
Each person
and inserting the following:(i) Assessment of fees.—Each person; andThe law already reads this way: § 379j–72(a)(1)(A)(i) already sets these words apart as their own provision.
Technical detail
already: /us/usc/t21/s379j–72/a/1/A/i holds the words already - Not carried out:
by adding at the end the following:
(ii) Applicable period.—For purposes of clause (i), the applicable period is—(I) for fiscal year 2026, the 12-month period ending on December 31, 2025; (II) for fiscal year 2027, the 9-month period ending on September 30, 2026; and (III) for fiscal year 2028 and each subsequent …
The law already reads this way: § 379j–72(a)(1)(A)(ii) is already as the bill would have it.
Technical detail
already there: /us/usc/t21/s379j–72/a/1/A/ii reads as the bill would have it - Carried out:
in subparagraph (B)(i), by amending subclause (I) to read as follows:
(I) has ceased all activities related to OTC monograph drugs prior to—(aa) for purposes of fiscal year 2026, January 1, 2025; (bb) for purposes of fiscal year 2027, January 1, 2026; and (cc) for purposes of fiscal year 2028 and each subsequent fiscal year, October 1 of the preceding fiscal year; and; and
- Carried out:
by amending subparagraph (D) to read as follows:
(D) Due date.—(i) Fiscal year 2026.—For fiscal year 2026, the facility fees required under subparagraph (A) shall be due on the later of—(I) the first business day of June of such year; or (II) the first business day after the enactment of an appropriations Act providing for the …
- Carried out:
Section 744M(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379j–72(b)) is amended to read as follows:
(b) Fee Revenue Amounts.—(1) In general.—For each of the fiscal years 2026 through 2030, fees under subsection (a)(1) shall be established to generate a total facility fee revenue amount equal to the sum of—(A) the annual base revenue for the fiscal year (as determined under …
- Not carried out:
by striking
subsection (b)(2)(B)
and insertingsubsection (b)(1)(B)
; and“subsection (b)(2)(B)” isn't in § 379j–72(c)(1)(A) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“subsection (b)(2)(B)” not found in /us/usc/t21/s379j–72/c/1/A - Not carried out:
by striking
fiscal year 2022 and each subsequent fiscal year
and insertingeach fiscal year
;“fiscal year 2022 and each subsequent fiscal year” isn't in § 379j–72(c)(1)(A) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“fiscal year 2022 and each subsequent fiscal year” not found in /us/usc/t21/s379j–72/c/1/A - Not carried out:
in subparagraph (B), by striking
fiscal year 2022
and all that follows through the period at the end and inserting the following: a fiscal year shall be equal to the product of—“(i) for fiscal year 2026—“(I) the fee for fiscal year 2025 under subsection (a)(2); and “(II) the inflation adjustment percentage under subparagraph (C); and “(ii) for each of fiscal years 2027 through 2030—“(I) the applicable fee under subsection (a)(2) for the preceding fiscal year; and “(II) the inflation adjustment percentage under subparagraph (C).; and“fiscal year 2022” isn't in § 379j–72(c)(1)(B) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“fiscal year 2022” not found in /us/usc/t21/s379j–72/c/1/B - Not carried out:
in the matter preceding clause (i), by inserting
the sum of
afteris equal to
;The law already reads this way: § 379j–72(c)(1)(C) already has “the sum of”.
Technical detail
already reads “the sum of” at that place in /us/usc/t21/s379j–72/c/1/C - Carried out:
by striking clause (i);
- Not carried out:
by redesignating subclauses (I) and (II) of clause (ii) as clauses (i) and (ii), respectively, and adjusting the margins accordingly;
We can't read how this instruction is worded yet, so it isn't shown in the text.
Technical detail
no-pattern: redesignating subclauses (X) and (X) of clause (X) as clauses (X) and (X), respectively, and adjusting the margins accordingly; - Not carried out:
by striking
(ii) for each of fiscal years 2024 and 2025, the sum of—
; and“(ii) for each of fiscal years 2024 and 2025, the sum of—” isn't in § 379j–72(c)(1)(C) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“(ii) for each of fiscal years 2024 and 2025, the sum of—” not found in /us/usc/t21/s379j–72/c/1/C - Not carried out:
in clause (ii), as so redesignated, by striking
Washington-Baltimore, DC–MD–VA–WV
and insertingWashington–Arlington–Alexandria–DC–VA–MD–WV
;“Washington-Baltimore, DC–MD–VA–WV” isn't in § 379j–72(c)(1)(C)(ii) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“Washington-Baltimore, DC–MD–VA–WV” not found in /us/usc/t21/s379j–72/c/1/C/ii - Not carried out:
by striking
fiscal year 2021 and subsequent fiscal years
and insertingeach fiscal year
;“fiscal year 2021 and subsequent fiscal years” isn't in § 379j–72(c)(2)(A) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“fiscal year 2021 and subsequent fiscal years” not found in /us/usc/t21/s379j–72/c/2/A - Not carried out:
by striking
subsections (b)(1)(B) and (b)(2)(C)
and insertingsubsection (b)(1)(C)
; and“subsections (b)(1)(B) and (b)(2)(C)” isn't in § 379j–72(c)(2)(A) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“subsections (b)(1)(B) and (b)(2)(C)” not found in /us/usc/t21/s379j–72/c/2/A - Not carried out:
by striking
the number of weeks specified in subparagraph (B)
and inserting10 weeks
;“the number of weeks specified in subparagraph (B)” isn't in § 379j–72(c)(2)(A) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“the number of weeks specified in subparagraph (B)” not found in /us/usc/t21/s379j–72/c/2/A - Carried out:
by striking subparagraph (B);
- Carried out:
by redesignating subparagraphs (C) and (D) as subparagraphs (B) and (C), respectively; and
- Not carried out:
in subparagraph (C), as so redesignated, by striking
paragraph (4) establishing
and insertingparagraph (5) publishing
;The bill points to subparagraph (C) of § 379j–72(c)(2), which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.
Technical detail
target not found: no subparagraph (C) in /us/usc/t21/s379j–72/c/2 - Not carried out:
in the matter preceding subparagraph (A), by striking
subsection (b)(2)(D)
and insertingsubsection (b)(1)(D)
; and“subsection (b)(2)(D)” isn't in § 379j–72(c)(3) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“subsection (b)(2)(D)” not found in /us/usc/t21/s379j–72/c/3 - Carried out:
by striking subparagraphs (A) through (E) and inserting the following:
(A) $135,000 for fiscal year 2026; (B) $300,000 for fiscal year 2027; (C) $55,000 for fiscal year 2028; (D) $30,000 for fiscal year 2029; and (E) $0 for fiscal year 2030.; and
- Carried out:
by striking paragraph (4) and inserting the following:
(4) One-time facility fee workload adjustment.—(A) In general.—In addition to the adjustments under paragraphs (1), (2), and (3), the Secretary may further increase the fee revenues and fees through a one-time adjustment made for fiscal year 2028, 2029, or 2030, in accordance …
- Not carried out:
in the subparagraph heading, by striking
in subsequent years
; and“in subsequent years” isn't in § 379j–72(f)(2)(D) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“in subsequent years” not found in /us/usc/t21/s379j–72/f/2/D - Not carried out:
by striking
(after fiscal year 2021)
; and“(after fiscal year 2021)” isn't in § 379j–72(f)(2)(D) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“(after fiscal year 2021)” not found in /us/usc/t21/s379j–72/f/2/D - Not carried out:
in paragraph (3), by striking
2021 through 2025
and inserting2026 through 2030
.“2021 through 2025” isn't in § 379j–72(f)(3) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“2021 through 2025” not found in /us/usc/t21/s379j–72/f/3
3 of the 26 changes this law makes here are already in the Code shown, which includes the law, so they are not marked.
§ 379j–72(a)(1)Facility fee(B)–(D)
Start of § 379j–72 to (a)(1)(B)(i)(II) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (B)(ii) | (ii) Contract manufacturing organizations | (ii) Contract manufacturing organizations | ||
| The amount of the fee for a contract manufacturing organization facility shall be equal to two-thirds of the amount of the fee for an OTC monograph drug facility that is not a contract manufacturing organization facility. | The amount of the fee for a contract manufacturing organization facility shall be equal to two-thirds of the amount of the fee for an OTC monograph drug facility that is not a contract manufacturing organization facility. | |||
| (C) | (C) Amount | (C) Amount | ||
| The amount of fees established under subparagraph (A) shall be established under subsection (c). | The amount of fees established under subparagraph (A) shall be established under subsection (c). | |||
| (D) | (D) Due date | (D) Due date[inserted: .—] | ||
| (D)(i) | (i) Fiscal year 2026 | (i) Fiscal year 2026[inserted: .—] | ||
| For fiscal year 2026, the facility fees required under subparagraph (A) shall be due on the later of— | For fiscal year 2026, the facility fees required under subparagraph (A) shall be due on the later of— | |||
| (D)(i)(I) | (I) | (I) | ||
| the first business day of June of such year; or | the first business day of June of such year; or | |||
| (D)(i)(II) | (II) | (II) | ||
| the first business day after the enactment of an appropriations Act providing for the collection and obligation of fees under this section for such year. | the first business day after the enactment of an appropriations Act providing for the collection and obligation of fees under this section for such year. | |||
| (D)(ii) | (ii) Fiscal year 2027 | (ii) Fiscal year 2027[inserted: .—] | ||
| For fiscal year 2027, the facility fees required under subparagraph (A) shall be due— | For fiscal year 2027, the facility fees required under subparagraph (A) shall be due— | |||
| (D)(ii)(I) | (I) | (I) | ||
| in a first installment representing 50 percent of such fee, on the later of— | in a first installment representing 50 percent of such fee, on the later of— |
§ 379j–72(a)(1)(D)Due date.—(ii)–(iii)
(a)(1)(D)(ii)(I)(aa)–(II) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (ii)(II)(aa) | (aa) | (aa) | ||
| February 1, 2027; or | February 1, 2027; or | |||
| (ii)(II)(bb) | (bb) | (bb) | ||
| if an appropriations Act described in subclause (I)(bb) is not in effect on February 1, 2027, the first business day after enactment of such an appropriations Act. | if an appropriations Act described in subclause (I)(bb) is not in effect on February 1, 2027, the first business day after enactment of such an appropriations Act. | |||
| (iii) | (iii) Subsequent fiscal years | (iii) Subsequent fiscal years[inserted: .—] | ||
| For fiscal year 2028 and each subsequent fiscal year, the facility fees required under subparagraph (A) shall be due on the later of— | For fiscal year 2028 and each subsequent fiscal year, the facility fees required under subparagraph (A) shall be due on the later of— | |||
| (iii)(I) | (I) | (I) | ||
| the first business day on or after October 1 of the fiscal year; or | the first business day on or after October 1 of the fiscal year; or |
§ 379j–72(a)–(b)
(a)(1)(D)(iii)(II)–(3)(A) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (a)(3)(B) | (B) Disputes concerning fees | (B) Disputes concerning fees | ||
| To qualify for the return of a fee claimed to have been paid in error under paragraph (1) or (2), a person shall submit to the Secretary a written request justifying such return within 180 calendar days after such fee was paid. | To qualify for the return of a fee claimed to have been paid in error under paragraph (1) or (2), a person shall submit to the Secretary a written request justifying such return within 180 calendar days after such fee was paid. | |||
| (a)(4) | (4) Notice | (4) Notice | ||
| Within the timeframe specified in subsection (c), the Secretary shall publish in the Federal Register the amount of the fees under paragraph (1) for such fiscal year. | Within the timeframe specified in subsection (c), the Secretary shall publish in the Federal Register the amount of the fees under paragraph (1) for such fiscal year. | |||
| (b) | (b) Fee | (b) Fee [inserted: Revenue] [inserted: Amounts.—] | ||
| (b)(1) | (1) In general | (1) In general[inserted: .—] | ||
| For each of the fiscal years 2026 through 2030, fees under subsection (a)(1) shall be established to generate a total facility fee revenue amount equal to the sum of— | For each of the fiscal years 2026 through 2030, fees under subsection (a)(1) shall be established to generate a total facility fee revenue amount equal to the sum of— | |||
| (b)(1)(A) | (A) | (A) | ||
| the annual base revenue for the fiscal year (as determined under paragraph (2)); | the annual base revenue for the fiscal year (as determined under paragraph (2)); |
§ 379j–72(b)–(c)
(b)(1)(B)–(E) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (b)(1)(E)(iii) | (iii) | (iii) | ||
| $854,000 for fiscal year 2028; and | $854,000 for fiscal year 2028; and | |||
| (b)(1)(F) | (F) | (F) | ||
| in the case of a fiscal year for which the Secretary applies the one-time facility fee workload adjustment under subsection (c)(4), the dollar amount equal to such adjustment. | in the case of a fiscal year for which the Secretary applies the one-time facility fee workload adjustment under subsection (c)(4), the dollar amount equal to such adjustment. | |||
| (b)(2) | (2) Annual base revenue | (2) Annual base revenue[inserted: .—] | ||
| For purposes of paragraph (1), the dollar amount of the annual base revenue for a fiscal year shall be— | For purposes of paragraph (1), the dollar amount of the annual base revenue for a fiscal year shall be— | |||
| (b)(2)(A) | (A) | (A) | ||
| for fiscal year 2026, the dollar amount of the total revenue amount established for fiscal year 2025 under this subsection as in effect on the day before | for fiscal year 2026, the dollar amount of the total revenue amount established for fiscal year 2025 under this subsection as in effect on the day before [inserted: the] [inserted: date] [inserted: of enactment of the Over-the-Counter Monograph Drug User Fee Amendments], not including any adjustments made for such fiscal year 2025 under subsection (c)(2), as so in effect; and | |||
| (b)(2)(B) | (B) | (B) | ||
| for fiscal years 2027 through 2030, the dollar amount of the total revenue amount established under this subsection for the previous fiscal year, not including any adjustments made for such previous fiscal year under subsection (c)(2) or (c)(3). | for fiscal years 2027 through 2030, the dollar amount of the total revenue amount established under this subsection for the previous fiscal year, not including any adjustments made for such previous fiscal year under subsection (c)(2) or (c)(3). | |||
| (c) | (c) Adjustments; annual fee setting | (c) Adjustments; annual fee setting |
§ 379j–72(c)Adjustments; annual fee setting(1)–(4)
(c)(1) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (1)(B)(ii)(II) | (II) | (II) | ||
| the inflation adjustment percentage under subparagraph (C). | the inflation adjustment percentage under subparagraph (C). | |||
| (1)(C) | (C) Inflation adjustment percentage | (C) Inflation adjustment percentage | ||
| The inflation adjustment percentage under this subparagraph for a fiscal year is equal to the sum of— | The inflation adjustment percentage under this subparagraph for a fiscal year is equal to the sum of— | |||
| (1)(C)(i) | (i) | |||
| (1)(C)(ii) | (ii) | (ii) | ||
| the average annual percent change that occurred in the Consumer Price Index for urban consumers (Washington–Arlington–Alexandria–DC–VA–MD–WV; Not Seasonally Adjusted; All items; Annual Index) for the first 3 years of the preceding 4 years of available data multiplied by the proportion of all costs other than personnel compensation and benefits costs to total costs of OTC monograph drug activities for the first 3 years of the preceding 4 fiscal years. | the average annual percent change that occurred in the Consumer Price Index for urban consumers (Washington–Arlington–Alexandria–DC–VA–MD–WV; Not Seasonally Adjusted; All items; Annual Index) for the first 3 years of the preceding 4 years of available data multiplied by the proportion of all costs other than personnel compensation and benefits costs to total costs of OTC monograph drug activities for the first 3 years of the preceding 4 fiscal years. | |||
| (2) | (2) Operating reserve adjustment | (2) Operating reserve adjustment | ||
| (2)(A) | (A) In general | (A) In general | ||
| For each fiscal year, for purposes of subsection (b)(1)(C), the Secretary may, in addition to adjustments under paragraph (1), further increase the fee revenue and fees if such an adjustment is necessary to provide operating reserves of carryover user fees for OTC monograph drug activities for not more than 10 weeks. | For each fiscal year, for purposes of subsection (b)(1)(C), the Secretary may, in addition to adjustments under paragraph (1), further increase the fee revenue and fees if such an adjustment is necessary to provide operating reserves of carryover user fees for OTC monograph drug activities for not more than 10 weeks. | |||
| (2)(B) | (B) | |||
| [inserted: (B)] Rationale for adjustment | ||||
| If an adjustment under this paragraph is made, the rationale for the amount of the increase or decrease (as applicable) in fee revenue and fees shall be contained in the annual Federal Register notice under paragraph (5) publishing fee revenue and fees for the fiscal year involved. | If an adjustment under this paragraph is made, the rationale for the amount of the increase or decrease (as applicable) in fee revenue and fees shall be contained in the annual Federal Register notice under paragraph (5) publishing fee revenue and fees for the fiscal year involved. | |||
| (3) | (3) Additional direct cost adjustment | (3) Additional direct cost adjustment | ||
| The Secretary shall, in addition to adjustments under paragraphs (1) and (2), further increase the fee revenue and fees for purposes of subsection (b)(1)(D) by an amount equal to— | The Secretary shall, in addition to adjustments under paragraphs (1) and (2), further increase the fee revenue and fees for purposes of subsection (b)(1)(D) by an amount equal to— | |||
| (3)(A) | (A) | (A) | ||
| $135,000 for fiscal year 2026; | $135,000 for fiscal year 2026; | |||
| (3)(B) | (B) | (B) | ||
| $300,000 for fiscal year 2027; | $300,000 for fiscal year 2027; | |||
| (3)(C) | (C) | (C) | ||
| $55,000 for fiscal year 2028; | $55,000 for fiscal year 2028; | |||
| (3)(D) | (D) [inserted: ] | |||
| [inserted: $30,000 for fiscal year 2029; and] | ||||
| (D) | ||||
| (3)(E) | (E) | (E) | ||
| $0 for fiscal year 2030. | $0 for fiscal year 2030. | |||
| (4) | (4) One-time facility fee workload adjustment | (4) One-time facility fee workload adjustment[inserted: .—] | ||
| (4)(A) | (A) In general | (A) In general[inserted: .—] | ||
| In addition to the adjustments under paragraphs (1), (2), and (3), the Secretary may further increase the fee revenues and fees through a one-time adjustment made for fiscal year 2028, 2029, or 2030, in accordance with this paragraph. | In addition to the adjustments under paragraphs (1), (2), and (3), the Secretary may further increase the fee revenues and fees through a one-time adjustment made for fiscal year 2028, 2029, or 2030, in accordance with this paragraph. | |||
| (4)(B) | (B) Adjustment described | (B) Adjustment described[inserted: .—] | ||
| (4)(B)(i) | (i) Conditions for adjustment | (i) Conditions for adjustment[inserted: .—] | ||
| An adjustment under this paragraph may be made for a fiscal year only if— | An adjustment under this paragraph may be made for a fiscal year only if— | |||
| (4)(B)(i)(I) | (I) | (I) | ||
| an adjustment under this paragraph had not been made for any prior fiscal year; | an adjustment under this paragraph had not been made for any prior fiscal year; | |||
| (4)(B)(i)(II) | (II) | (II) | ||
| the average number of OTC monograph drug facilities subject to a facility fee under subsection (a)(1) over the period of the preceding 3 fiscal years exceeds 1,625; and | the average number of OTC monograph drug facilities subject to a facility fee under subsection (a)(1) over the period of the preceding 3 fiscal years exceeds 1,625; and | |||
| (4)(B)(i)(III) | (III) | (III) | ||
| with respect to facilities described in subclause (II), the average number of such facilities (expressed as a percentage) that appeared on the arrears lists pursuant to subsection (e)(1)(A)(i) over the period of the preceding 3 fiscal years is less than 30 percent. | with respect to facilities described in subclause (II), the average number of such facilities (expressed as a percentage) that appeared on the arrears lists pursuant to subsection (e)(1)(A)(i) over the period of the preceding 3 fiscal years is less than 30 percent. | |||
| (4)(B)(ii) | (ii) Amount of adjustment | (ii) Amount of adjustment[inserted: .—] | ||
| An adjustment under this paragraph for a fiscal year shall equal the product of— | An adjustment under this paragraph for a fiscal year shall equal the product of— | |||
| (4)(B)(ii)(I) | (I) | (I) | ||
| the total facility revenue amount determined under subsection (b) for the fiscal year, exclusive of the adjustment under this paragraph for such fiscal year; and | the total facility revenue amount determined under subsection (b) for the fiscal year, exclusive of the adjustment under this paragraph for such fiscal year; and | |||
| (4)(B)(ii)(II) | (II) | (II) | ||
| the excess facility percentage described in clause (iii). | the excess facility percentage described in clause (iii). | |||
| (4)(B)(iii) | (iii) Excess facility percentage | (iii) Excess facility percentage[inserted: .—] | ||
| The excess facility percentage described in this clause is— | The excess facility percentage described in this clause is— | |||
| (4)(B)(iii)(I) | (I) | (I) | ||
| the amount by which the average number of OTC monograph drug facilities subject to a facility fee under subsection (a)(1) over the preceding 3 fiscal years exceeds 1,625; divided by | the amount by which the average number of OTC monograph drug facilities subject to a facility fee under subsection (a)(1) over the preceding 3 fiscal years exceeds 1,625; divided by | |||
Rest of § 379j–72 unchanged
21 U.S.C. § 379j–73 Reauthorization; reporting requirements
6 changes the bill asks for here, 1 carried out
- Not carried out:
by striking
Beginning with fiscal year 2021, and not later than 120 calendar days after the end of each fiscal year thereafter
and inserting the following:(1) In general.—Not later than 120 calendar days after the end of each fiscal year;The law already reads this way: § 379j–73(a)(1) already sets these words apart as their own provision.
Technical detail
already: /us/usc/t21/s379j–73/a/1 holds the words already - Not carried out:
by striking
section 3861(b) of the CARES Act
and insertingsection 6502 of the Over-the-Counter Monograph Drug User Fee Amendments
; and“section 3861(b) of the CARES Act” isn't in § 379j–73(a) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“section 3861(b) of the CARES Act” not found in /us/usc/t21/s379j–73/a - Carried out:
by adding at the end the following:
(2) Additional information.—Beginning with fiscal year 2026, the annual report under this subsection shall include—(A) the progress of the Food and Drug Administration in achieving the goals, and future plans for meeting the goals, including—(i) the number of Tier 1 OTC …
The section already has a provision under this letter or number, so it would have two.
- Not carried out:
in subsection (b), by striking
fiscal year 2021 and each subsequent fiscal year
and insertingeach fiscal year
; and“fiscal year 2021 and each subsequent fiscal year” isn't in § 379j–73(b) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“fiscal year 2021 and each subsequent fiscal year” not found in /us/usc/t21/s379j–73/b - Not carried out:
by striking
2025
each place it appears and inserting2030
; and“2025” isn't in § 379j–73(d) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“2025” not found in /us/usc/t21/s379j–73/d - Not carried out:
by adding at the end the following:
(4) Minutes of negotiation meetings.—(A) Public availability.—The Secretary shall make publicly available, on the public website of the Food and Drug Administration, robust written minutes of all negotiation meetings conducted under this subsection between the Food and Drug …
The law already reads this way: § 379j–73(d)(4) is already as the bill would have it.
Technical detail
already there: /us/usc/t21/s379j–73/d/4 reads as the bill would have it
This law puts a provision under a letter or number this section already has. The Code shown already includes the law, so the provision there may be the one it added.
2 of the 6 changes this law makes here are already in the Code shown, which includes the law, so they are not marked.
§ 379j–73(a)–(c)
Start of § 379j–73 to (a)(2)(C)(ii) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (a)(2)(D) | (D) | (D) | ||
| the progress of the Food and Drug Administration in allowing nonclinical testing alternatives to animal testing for the consideration of sunscreen active ingredients. | the progress of the Food and Drug Administration in allowing nonclinical testing alternatives to animal testing for the consideration of sunscreen active ingredients. | |||
| (a)(3) | (3) Confidentiality | (3) Confidentiality | ||
| Nothing in paragraph (2) shall be construed to authorize the disclosure of information that is prohibited from disclosure under section 331(j) of this title or section 1905 of title 18 or that is subject to withholding under section 552(b)(4) of title 5. | Nothing in paragraph (2) shall be construed to authorize the disclosure of information that is prohibited from disclosure under section 331(j) of this title or section 1905 of title 18 or that is subject to withholding under section 552(b)(4) of title 5. | |||
| (a)(2) | (2) [inserted: Additional information.—] | |||
| [inserted: Beginning with fiscal year 2026, the annual report under this subsection shall include—] | ||||
| (a)(2)(A) | (A) [inserted: ] | |||
| [inserted: the progress of the Food and Drug Administration in achieving the goals, and future plans for meeting the goals, including—] | ||||
| (a)(2)(A)(i) | (i) [inserted: ] | |||
| [inserted: the number of Tier 1 OTC monograph order requests for which a proposed order was issued, and the number of such requests for which a final order was issued, in the previous fiscal year;] | ||||
| (a)(2)(A)(ii) | (ii) [inserted: ] | |||
| [inserted: the number of Tier 2 OTC monograph order requests for which a proposed order was issued, and the number of such requests for which a final order was issued, in the previous fiscal year;] | ||||
| (a)(2)(A)(iii) | (iii) [inserted: ] | |||
| [inserted: the number of specified safety OTC monograph order requests for which a proposed order was issued, and the number of such requests for which a final order was issued, in the previous fiscal year;] | ||||
| (a)(2)(A)(iv) | (iv) [inserted: ] | |||
| [inserted: the number of generally recognized as safe and effective finalization OTC monograph order requests for which a proposed order was issued, and the number of such requests for which a final order was issued, in the previous fiscal year;] | ||||
| (a)(2)(A)(v) | (v) [inserted: ] | |||
| [inserted: the average timeline for processing OTC monograph order requests, in the aggregate and by submission type, in the previous fiscal year; and] | ||||
| (a)(2)(A)(vi) | (vi) [inserted: ] | |||
| [inserted: postmarket safety activities with respect to OTC monograph drugs, including—] | ||||
| (a)(2)(A)(vi)(I) | (I) [inserted: ] | |||
| [inserted: collecting, developing, and reviewing safety information on OTC monograph drugs, including adverse event reports;] | ||||
| (a)(2)(A)(vi)(II) | (II) [inserted: ] | |||
| [inserted: developing and using improved analytical tools, adverse event data-collection systems, including information technology systems, to assess potential safety problems, including access to external databases; and] | ||||
| (a)(2)(A)(vi)(III) | (III) [inserted: ] | |||
| [inserted: activities under section 760;] | ||||
| (a)(2)(B) | (B) [inserted: ] | |||
| [inserted: information regarding registration of OTC monograph drug facilities and contract manufacturing organization facilities and payment of registration fees by such facilities, including—] | ||||
| (a)(2)(B)(i) | (i) [inserted: ] | |||
| [inserted: the OTC monograph drug facilities and contract manufacturing organization facilities that were first registered under section 510(c) or 510(i) in the fiscal year; and] | ||||
| (a)(2)(B)(ii) | (ii) [inserted: ] | |||
| [inserted: for each OTC monograph drug facility and contract manufacturing organization facility that was assessed a facility fee under section 744M(a) in the fiscal year, whether the facility paid such fee;] | ||||
| (a)(2)(C) | (C) [inserted: ] | |||
| [inserted: the status of implementation of evidence and testing standards under section 505G(r) for nonprescription drugs intended for topical administration, including—] | ||||
| (a)(2)(C)(i) | (i) [inserted: ] | |||
| [inserted: the application of evidence or testing standards; and] | ||||
| (a)(2)(C)(ii) | (ii) [inserted: ] | |||
| [inserted: the number of active ingredient requests for nonprescription drugs intended for topical administration reviewed using the standards under section 505G(b); and] | ||||
| (a)(2)(D) | (D) [inserted: ] | |||
| [inserted: the progress of the Food and Drug Administration in allowing nonclinical testing alternatives to animal testing for the consideration of sunscreen active ingredients.] | ||||
| (a)(3) | (3) [inserted: Confidentiality.—] | |||
| [inserted: Nothing in paragraph (2) shall be construed to authorize the disclosure of information that is prohibited from disclosure under section 301(j) of this Act or section 1905 of title 18, United States Code, or that is subject to withholding under section 552(b)(4) of title 5, United States Code.] | ||||
| (b) | (b) Fiscal report | (b) Fiscal report | ||
| Not later than 120 calendar days after the end of each fiscal year for which fees are collected under this subpart, the Secretary shall prepare and submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report on the implementation of the authority for such fees during such fiscal year and the use, by the Food and Drug Administration, of the fees collected for such fiscal year. | Not later than 120 calendar days after the end of each fiscal year for which fees are collected under this subpart, the Secretary shall prepare and submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report on the implementation of the authority for such fees during such fiscal year and the use, by the Food and Drug Administration, of the fees collected for such fiscal year. | |||
| (c) | (c) Public availability | (c) Public availability | ||
| The Secretary shall make the reports required under subsections (a) and (b) available to the public on the internet website of the Food and Drug Administration. | The Secretary shall make the reports required under subsections (a) and (b) available to the public on the internet website of the Food and Drug Administration. | |||
Rest of § 379j–73 unchanged
42 U.S.C. § 254b–2 Community health centers and the National Health Service Corps Fund
5 changes the bill asks for here, 2 carried out
- Not carried out:
in subparagraph (I), by striking
and
at the end; andThe bill strikes “and” at the end of § 254b–2(b)(1)(I), but the text there doesn't end with it. The law may have changed since the bill was drafted.
Technical detail
“and” is not at the end of /us/usc/t42/s254b–2/b/1/I - Carried out:
by adding at the end the following:
(K) $1,423,890,411 for the period beginning on October 1, 2025, and ending on January 30, 2026; and.
The section already has a provision under this letter or number, so it would have two.
- Not carried out:
in subparagraph (J), by striking
and
at the end;The bill strikes “and” at the end of § 254b–2(b)(2)(J), but the text there doesn't end with it. The law may have changed since the bill was drafted.
Technical detail
“and” is not at the end of /us/usc/t42/s254b–2/b/2/J - Not carried out:
in subparagraph (K), by striking the period at the end and inserting
; and
; andThe bill strikes “.” at the end of § 254b–2(b)(2)(K), but the text there doesn't end with it. The law may have changed since the bill was drafted.
Technical detail
“.” is not at the end of /us/usc/t42/s254b–2/b/2/K - Carried out:
by adding at the end the following:
(L) $115,315,068 for the period beginning on October 1, 2025, and ending on January 30, 2026..
The section already has a provision under this letter or number, so it would have two.
This law puts a provision under a letter or number this section already has. The Code shown already includes the law, so the provision there may be the one it added.
§ 254b–2(b)Funding(1)–(2)
Start of § 254b–2 to (b)(1)(I) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (1)(J) | (J) | (J) | ||
| $4,600,000,000 for fiscal year 2026; and | $4,600,000,000 for fiscal year 2026; and | |||
| (1)(K) | (K) | (K) | ||
| $1,159,452,055 for the period beginning on October 1, 2026, and ending on December 31, 2026; and | $1,159,452,055 for the period beginning on October 1, 2026, and ending on December 31, 2026; and | |||
| (1)(K) | (K) [inserted: ] | |||
| [inserted: $1,423,890,411 for the period beginning on October 1, 2025, and ending on January 30, 2026; and] | ||||
| (2) | (2) | (2) | ||
| to be transferred to the Secretary of Health and Human Services to provide enhanced funding for the National Health Service Corps— | to be transferred to the Secretary of Health and Human Services to provide enhanced funding for the National Health Service Corps— | |||
| (2)(A) | (A) | (A) | ||
| $290,000,000 for fiscal year 2011; | $290,000,000 for fiscal year 2011; | |||
§ 254b–2(b)–(e)
(b)(2)(B)–(J) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (b)(2)(K) | (K) | (K) | ||
| $350,000,000 for fiscal year 2026; and | $350,000,000 for fiscal year 2026; and | |||
| (b)(2)(L) | (L) | (L) | ||
| $88,219,178 for the period beginning on October 1, 2026, and ending on December 31, 2026. | $88,219,178 for the period beginning on October 1, 2026, and ending on December 31, 2026. | |||
| (b)(2)(L) | (L) [inserted: ] | |||
| [inserted: $115,315,068 for the period beginning on October 1, 2025, and ending on January 30, 2026.] | ||||
| (c) | (c) Construction | (c) Construction | ||
| There is authorized to be appropriated, and there is appropriated, out of any monies in the Treasury not otherwise appropriated, $1,500,000,000 to be available for fiscal years 2011 through 2015 to be used by the Secretary of Health and Human Services for the construction and renovation of community health centers. | There is authorized to be appropriated, and there is appropriated, out of any monies in the Treasury not otherwise appropriated, $1,500,000,000 to be available for fiscal years 2011 through 2015 to be used by the Secretary of Health and Human Services for the construction and renovation of community health centers. | |||
| (d) | (d) Use of fund | (d) Use of fund | ||
| The Secretary of Health and Human Services shall transfer amounts in the CHC Fund to accounts within the Department of Health and Human Services to increase funding, over the fiscal year 2008 level, for community health centers and the National Health Service Corps. | The Secretary of Health and Human Services shall transfer amounts in the CHC Fund to accounts within the Department of Health and Human Services to increase funding, over the fiscal year 2008 level, for community health centers and the National Health Service Corps. | |||
| (e) | (e) Availability | (e) Availability | ||
| Amounts appropriated under subsections (b) and (c) shall remain available until expended. | Amounts appropriated under subsections (b) and (c) shall remain available until expended. | |||
42 U.S.C. § 254c–2 Special diabetes programs for type I diabetes
3 changes the bill asks for here, 1 carried out
- Not carried out:
in subparagraph (F), by striking
and
at the end;The bill strikes “and” at the end of § 254c–2(b)(2)(F), but the text there doesn't end with it. The law may have changed since the bill was drafted.
Technical detail
“and” is not at the end of /us/usc/t42/s254c–2/b/2/F - Not carried out:
in subparagraph (G), by striking the period at the end and inserting
; and
; andThe bill strikes “.” at the end of § 254c–2(b)(2)(G), but the text there doesn't end with it. The law may have changed since the bill was drafted.
Technical detail
“.” is not at the end of /us/usc/t42/s254c–2/b/2/G - Carried out:
by adding at the end the following:
(H) $53,145,205 for the period beginning on October 1, 2025, and ending on January 30, 2026, to remain available until expended..
The section already has a provision under this letter or number, so it would have two.
This law puts a provision under a letter or number this section already has. The Code shown already includes the law, so the provision there may be the one it added.
§ 254c–2(b)(2)Appropriations(G)–(H)
Start of § 254c–2 to (b)(2)(F) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (G) | (G) | (G) | ||
| $200,000,000 for fiscal year 2026, to remain available until expended; and | $200,000,000 for fiscal year 2026, to remain available until expended; and | |||
| (H) | (H) | (H) | ||
| $50,410,959 for the period beginning on October 1, 2026, and ending on December 31, 2026, to remain available until expended. | $50,410,959 for the period beginning on October 1, 2026, and ending on December 31, 2026, to remain available until expended. | |||
| (H) | (H) [inserted: ] | |||
| [inserted: $53,145,205 for the period beginning on October 1, 2025, and ending on January 30, 2026, to remain available until expended.] | ||||